RINVOQ is the first and only systemic medication approved in the European Union to treat adult and adolescent patients with non-segmental vitiligo (NSV) who are candidates for systemic ...
AbbVie (NYSE: ABBV) will announce its third-quarter 2026 financial results on Friday, October 30, 2026, before the market opens. AbbVie will host a live webcast of the earnings conference call ...
AbbVie presents 60 abstracts and presentations from a robust portfolio spanning across alopecia areata, atopic dermatitis, hidradenitis suppurativa, non-segmental vitiligo, psoriasis and ...
JUVMO™ is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson's disease1 Taken once daily with or without levodopa therapy, JUVMO offers patients ...
Phase 2 data in adults with atopic dermatitis showed that all three zumilokibart dose regimens met the primary endpoint, with significantly greater improvements in Eczema Area and Severity ...
RINVOQ is now approved in the European Union for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients two years of age and older who have responded ...
Multi-year partnership applies Iambic's AI platform to speed up small molecule drug discovery in immunology, neuroscience and oncology Companies to pursue programs with both first-in-class ...
On behalf of AbbVie, Perry Siatis, Executive Vice President, General Counsel and Secretary, testified in front of the U.S. Trade Representative (USTR) ...
SKIN360 marks the first in a series of assessment protocols addressing patients' evolving aesthetic goals. The program includes provider education and resources to support 96% ...
New data from prospective real-world studies of VRAYLAR showed meaningful improvements in depressive symptoms, functioning and quality of life among adults living with major depressive ...
NORTH CHICAGO, Ill., Sept. 17, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that new data from its broad multiple myeloma research portfolio will be featured at the 23 rd International ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results